8-K: SelectQuote Faces NYSE Delisting Threat Over Low Stock Price

SelectQuote, Inc. received a notice from the NYSE for non-compliance due to its common stock trading below $1.00 for 30 consecutive days, initiating a six-month cure period.

Summary

• SelectQuote, Inc. received a notice from the New York Stock Exchange (NYSE) on March 19, 2026, indicating non-compliance with Section 802.01C of the NYSE Listed Company Manual.
• The non-compliance stems from the company's common stock having an average closing price of less than $1.00 per share over a consecutive 30 trading-day period.
• The company has a six-month cure period to regain compliance, which requires its common stock to achieve a closing price of at least $1.00 and an average closing price of at least $1.00 over the 30 trading-day period ending on the last trading day of any calendar month during this period.
• SelectQuote intends to notify the NYSE of its plan to cure the deficiency and will closely monitor its stock price, considering available alternatives if necessary to regain compliance.
• During the cure period, SelectQuote's common stock will continue to be listed and traded on the NYSE, provided the company complies with other NYSE continued listing standards.
• The company recently reported strong fiscal second quarter 2026 results on February 5th and secured a new $415 million credit facility, extending the majority of its debt maturities to 2031.
• SelectQuote projects fiscal 2026 operating cash flow in the range of $25 million to $35 million and anticipates generating meaningful cash flow growth in future years.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the delisting threat, despite management's stated intent to cure and positive financial projections. The market's valuation below $1.00 indicates deep-seated concerns.

Positives

• Recently reported strong fiscal second quarter 2026 results on February 5th.
• Executed a new $415 million credit facility, extending the majority of its debt maturities to 2031.
• Maintains a strong liquidity position and robust operating cash flow outlook, providing operational flexibility to execute its strategy.
• Projects fiscal 2026 operating cash flow in the range of $25 million to $35 million.
• Expects the business to continue generating meaningful cash flow growth in years to come.

Negatives

• Received a notice from the NYSE for non-compliance with Section 802.01C due to its common stock trading below $1.00 per share on average for 30 consecutive trading days.
• Faces potential delisting from the NYSE if compliance with the minimum stock price requirement is not regained within the six-month cure period.

Risks

• Inability to regain compliance with NYSE continued listing standards within the six-month cure period.
• Failure to continue to comply with other applicable NYSE listing standards.
• Reliance on a limited number of insurance carrier partners and potential termination of those relationships or failure to develop new ones.
• Impact of existing and future laws and regulations affecting the health insurance market.
• Changes in health insurance products offered by insurance carrier partners and the health insurance market generally.
• Competition from other brokers, exclusively online brokers, carriers selling directly to consumers, and government-run health insurance exchanges.
• Dependence on revenue from carriers in the senior segment and potential downturns in the senior health, life, automotive, and home insurance industries.
• Challenges in developing new offerings and penetrating new vertical markets.
• Risks associated with third-party products.
• Failure to enroll individuals during the Medicare annual enrollment period.
• Difficulties in attracting, integrating, and retaining qualified personnel.
• Dependence on lead providers and ability to compete for leads, as well as failure to obtain and/or convert sales leads to actual sales.
• Issues with access to data from consumers and insurance carriers, and accuracy of information provided.
• Challenges in cost-effective advertisement through internet search engines and ability to contact consumers by telephone.
• Impact of global economic conditions, including inflation.
• Disruption to operations as a result of future acquisitions.
• Reliance on significant estimates and assumptions in the preparation of financial statements and potential impairment of goodwill.
• Potential litigation and other legal proceedings or inquiries.
• Existing and future indebtedness and the ability to maintain compliance with debt covenants.
• Access to additional capital.
• Failure to protect intellectual property and the company's brand.
• Fluctuations in financial results caused by seasonality.
• Accuracy and timeliness of commissions reports from insurance carriers and timing of insurance carriers' approval and payment practices.
• Factors that impact the estimate of the constrained lifetime value of commissions per policyholder.
• Changes in accounting rules, tax legislation, and other legislation.
• Disruptions or failures of technological infrastructure and platform.
• Failure to maintain relationships with third-party service providers.
• Cybersecurity breaches or other attacks involving company systems or those of its insurance carrier partners or third-party service providers.
• Ability to protect consumer information and other data.
• Failure to market and sell Medicare plans effectively or in compliance with laws.
• Factors related to the pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates, and regulatory changes or other industry developments.

Future Outlook

SelectQuote intends to notify the NYSE of its plan to cure the stock price deficiency and will closely monitor its stock price during the six-month cure period, considering available alternatives if necessary to maintain its NYSE listing. The company also projects fiscal 2026 operating cash flow between $25 million and $35 million and expects to generate meaningful cash flow growth in the years to come.

Management Comments

• The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard.
• The Company intends to closely monitor its stock price during the cure period and will, if necessary, consider available alternatives to cure the stock price deficiency.
• SelectQuote's strong liquidity position and robust operating cash flow outlook provide the Company operational flexibility to execute its strategy and achieve its goals.
• The Company plans to take appropriate actions if necessary to maintain its listing on the NYSE.

Industry Context

StockSavvy.ai notes that the NYSE delisting notice for trading below $1.00 is a common challenge for smaller-cap companies facing market headwinds or operational difficulties. While SelectQuote highlights its recent financial performance and liquidity, the stock price performance indicates significant investor concern, potentially reflecting broader skepticism in the insurance brokerage sector or specific company-related issues not fully addressed by the stated positives.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Face uncertainty regarding the company's continued listing on the NYSE, potential for further stock price volatility, and possible dilution if a reverse stock split or other equity-based cure is pursued.
• Employees: No direct impact mentioned, but prolonged uncertainty or delisting could affect morale or future compensation plans tied to stock performance.
• Creditors: The new $415 million credit facility extends maturities to 2031, which is positive, but a delisting could potentially trigger covenants or make future financing more challenging.
• Customers/Suppliers: No direct impact mentioned from the delisting notice itself.

Next Steps

• SelectQuote will notify the NYSE of its intent to cure the stock price deficiency.
• The company will closely monitor its stock price during the six-month cure period.
• SelectQuote will consider available alternatives to cure the stock price deficiency if necessary.
• The company plans to take appropriate actions to maintain its listing on the NYSE.
• The company expects to continue generating meaningful cash flow growth in years to come.

Key Dates

Recommendation

The NYSE delisting notice is a severe indicator of market distress and investor lack of confidence, typically leading to further downward pressure on the stock. While the company has a cure period and highlights some positives, the fundamental issue of sustained sub-$1.00 trading suggests deeper problems. The risk of delisting, even with a cure period, creates significant uncertainty and makes the stock highly speculative. Seasoned investors would likely exit to avoid further capital erosion and reallocate to more stable opportunities.

Keywords

SelectQuote, SLQT, NYSE, Delisting Notice, Stock Price Deficiency, Compliance, Financial Reporting, Insurance Broker, Medicare, Healthcare Services, Credit Facility, Operating Cash Flow